RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Recommendation of “Hold” by Brokerages

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has been given an average rating of “Hold” by the thirteen analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $9.56.

Several equities analysts recently commented on the company. JPMorgan Chase & Co. lowered RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a report on Monday, November 11th. Wells Fargo & Company cut their target price on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. Piper Sandler downgraded RAPT Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $8.00 to $2.00 in a report on Monday, November 11th. HC Wainwright raised shares of RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a report on Thursday, December 26th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $2.00 price objective (down previously from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Readystate Asset Management LP acquired a new position in RAPT Therapeutics during the third quarter worth about $36,000. JPMorgan Chase & Co. lifted its stake in RAPT Therapeutics by 298.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after buying an additional 25,130 shares in the last quarter. Barclays PLC grew its holdings in RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after buying an additional 29,195 shares during the last quarter. XTX Topco Ltd purchased a new position in RAPT Therapeutics during the second quarter worth $108,000. Finally, SG Americas Securities LLC raised its holdings in shares of RAPT Therapeutics by 401.9% in the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock worth $84,000 after acquiring an additional 42,636 shares during the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Stock Performance

Shares of RAPT opened at $1.18 on Wednesday. RAPT Therapeutics has a 1 year low of $0.79 and a 1 year high of $27.35. The stock has a market capitalization of $41.25 million and a PE ratio of -0.43. The stock has a 50-day simple moving average of $1.25 and a 200-day simple moving average of $1.90.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. Analysts predict that RAPT Therapeutics will post -2.43 EPS for the current year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.